BBA
YMAB

Baker Bros. Advisors’s Y-mAbs Therapeutics YMAB Stock Holding History

Baker Bros. Advisors’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-138,514
Closed -$4.33M – 113
2019
Q4 		$4.33M Buy
138,514
+35,714
+35% +$1.06M 0.02% 75
2019
Q3 		$2.68M Hold
102,800
– – 0.02% 82
2019
Q2 		$2.35M Hold
102,800
– – 0.02% 79
2019
Q1 		$2.69M Hold
102,800
– – 0.02% 75
2018
Q4 		$2.09M Sell
102,800
-47,200
-31% -$1.08M 0.02% 72
2018
Q3 		$3.98M Buy
+150,000
New +$3.81M 0.03% 75

Other funds holding YMAB

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Baker Bros. Advisors's YMAB Position: Q1 2020 in Review

Baker Bros. Advisors sold out of Y-mAbs Therapeutics (YMAB) in Q1 2020, closing a stake of 138,514 shares — an estimated $4.33M sold.

Baker Bros. Advisors first reported a position in YMAB in Q3 2018 and held it in 6 quarters. The position peaked at $4.33M in Q4 2019. 80 funds tracked by Wall St. Rank hold YMAB as of Q1 2020.

  • Baker Bros. Advisors reported no remaining Y-mAbs Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Baker Bros. Advisors sold 138,514 Y-mAbs Therapeutics shares in Q1 2020, an estimated $4.33M.
  • Baker Bros. Advisors first reported a position in Y-mAbs Therapeutics in Q3 2018 and held it in 6 quarters.
  • Baker Bros. Advisors's Y-mAbs Therapeutics position peaked at $4.33M in Q4 2019.
  • 80 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2020.

Based on Baker Bros. Advisors's 13F filing for Q1 2020, filed 15 May 2020.